tiprankstipranks
Trending News
More News >
MCI Onehealth Technologies, Inc. Class A (TSE:AIDX)
TSX:AIDX

MCI Onehealth Technologies, Inc. Class A (AIDX) AI Stock Analysis

Compare
113 Followers

Top Page

TS

MCI Onehealth Technologies, Inc. Class A

(TSX:AIDX)

Rating:44Neutral
Price Target:
C$1.00
▼(-27.54%Downside)
Overall, MCI Onehealth Technologies shows strong strategic initiatives and significant expansions, which could improve its market position. However, the current financial performance struggles and technical indicators reflect bearish sentiment and operational inefficiencies, leading to a low overall score. The stock is currently unattractive due to its ongoing losses and negative cash flow, despite potential future upside from strategic corporate events.
Positive Factors
Earnings
The company's revenue increased by 208% year-over-year, surpassing both estimates and consensus.
Future Projections
Orion is projected to generate more than C$100M in revenue in 2025 and over C$20M in adjusted EBITDA, which should more than double HEALWELL's revenue and bring the company to positive EBITDA in 2025.
Strategic Acquisition
The transformational acquisition of two segments of Orion Health and partnership with WELL Health Technologies are expected to enhance financial performance.
Negative Factors
Financial Performance
Adjusted EBITDA loss of (C$5.6M) was wider than estimates and consensus.
Revenue Expectations
Revenue is expected to be softer in the first half of the year due to a cutback on early-stage trials.
Share Count Impact
The primary reason for the lower price target is due to factoring in a higher share count.

MCI Onehealth Technologies, Inc. Class A (AIDX) vs. iShares MSCI Canada ETF (EWC)

MCI Onehealth Technologies, Inc. Class A Business Overview & Revenue Model

Company DescriptionHealwell AI Inc., a healthcare technology company, focuses on AI and data science for preventative care. It offers AI-enabled decision support platform for healthcare providers. Healwell AI Inc. has a strategic alliance agreement with WELL Health Technologies Corp to enhance the growth and development of AI-enabled healthcare technologies. The company was formerly known as MCI Onehealth Technologies Inc. and changed its name to Healwell AI Inc. in October 2023. Healwell AI Inc. was incorporated in 2012 and is headquartered in Toronto, Canada.
How the Company Makes MoneyMCI Onehealth Technologies generates revenue through multiple streams. The primary source of income is its network of healthcare clinics and services, where it offers primary and specialty medical care to patients. The company also earns money by licensing its digital health technology solutions to other healthcare providers, enabling them to improve patient management and operational efficiency. Additionally, strategic partnerships and collaborations with other healthcare organizations and technology companies contribute to its revenue, allowing for the integration and expansion of its services across various platforms.

MCI Onehealth Technologies, Inc. Class A Earnings Call Summary

Earnings Call Date:May 13, 2025
(Q3-2024)
|
% Change Since: -8.61%|
Next Earnings Date:Aug 18, 2025
Earnings Call Sentiment Neutral
Healwell AI's earnings call reflects a strong growth trajectory fueled by strategic acquisitions and expansion in AI and data science segments. Despite facing challenges such as increased net loss and adjusted EBITDA loss, the company has made significant progress in revenue growth and strategic partnerships. The impact of external factors like the Inflation Reduction Act poses challenges, but the company remains optimistic about future growth and profitability.
Q3-2024 Updates
Positive Updates
Significant Revenue Growth
Healwell achieved quarterly revenues of $13.7 million in Q3 2024, compared to $1.6 million in the same quarter last year, driven by recent acquisitions.
AI and Data Science Segment Expansion
The AI and data science segment experienced an impressive 2,800% revenue growth this quarter as compared to the same quarter of 2023.
Increase in Master Service Agreements
Healwell's AI and data science subsidiaries executed 5 new MSAs in Q3 2024, bringing the cumulative total to 27, including partnerships with 7 of the top 10 largest pharmaceutical companies.
Strategic Acquisitions and Expansion
Acquired VeroSource Solutions and BioPharma Services, enhancing clinical research capabilities and financial profile. Expanded clinical research services for the pharmaceutical industry.
Prix Galien USA 2024 Award
Pentavere received the prestigious Prix Galien USA 2024 Award for Best Digital Health start-up in AI for life sciences.
Negative Updates
Adjusted EBITDA Loss
Healwell reported an adjusted EBITDA loss of $3.4 million in Q3 2024 compared to a loss of $2.5 million in Q3 2023.
Net Loss Increase
Reported a net loss of $11.1 million in Q3 2024, compared to a loss of $7.7 million in Q3 2023.
Impact of Inflation Reduction Act
BioPharma's early-stage trial revenue expectations were impacted due to volatility in the pharmaceutical industry caused by the Inflation Reduction Act.
Company Guidance
During the Q3 2024 earnings call for Healwell AI, the company provided a comprehensive overview of its financial and strategic progress. Key financial metrics included a significant increase in quarterly revenue to CAD 13.7 million from CAD 1.6 million the previous year, primarily driven by strategic acquisitions. Adjusted gross profit rose to CAD 5.9 million, with a gross margin of 43%, up from 20% in Q3 2023. However, the company reported an adjusted EBITDA loss of CAD 3.4 million and a net loss of CAD 11.1 million. The call highlighted the company's impressive growth trajectory, with annualized revenue run rate increasing eightfold to CAD 58.4 million. Strategic acquisitions, such as VeroSource Solutions and BioPharma Services, were noted as transformational, enhancing Healwell's financial profile and capabilities. The company anticipates reaching a CAD 100 million revenue run rate and profitability on an adjusted EBITDA basis in the near future. Healwell also emphasized its expansion in AI solutions and clinical research, with 27 signed master service agreements with life sciences partners, including seven of the top ten largest pharmaceutical companies.

MCI Onehealth Technologies, Inc. Class A Financial Statement Overview

Summary
Strong revenue growth is overshadowed by ongoing profitability challenges, negative operating cash flows, and negative net income, indicating significant operational inefficiencies.
Income Statement
45
Neutral
The company has shown significant revenue growth from 2023 to 2024, but this growth has not translated into profitability. The gross profit margin is reasonable, but net income remains negative, indicating ongoing challenges in managing expenses relative to revenue. EBIT and EBITDA margins are also negative, which highlights operational inefficiencies.
Balance Sheet
50
Neutral
The debt-to-equity ratio shows a moderate level of leverage, but the company has been able to maintain a positive equity ratio. Return on equity is negative due to continued net losses, which is concerning for long-term financial health. The balance sheet reflects an increase in total assets and equity, indicating some stability.
Cash Flow
40
Negative
The company is experiencing negative operating cash flow and free cash flow, which is worrisome. However, there has been a significant increase in financing cash flow, which may support operations temporarily. The free cash flow to net income ratio is unfavorable, indicating that the company is not generating cash efficiently.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue38.97M7.32M10.42M47.82M38.57M
Gross Profit17.32M1.26M3.71M15.01M64.22M
EBITDA-18.42M-16.11M-13.94M-11.44M2.11M
Net Income-26.29M-31.60M-21.09M-15.67M-1.03M
Balance Sheet
Total Assets125.53M53.70M45.63M60.89M22.36M
Cash, Cash Equivalents and Short-Term Investments9.68M19.16M1.80M7.68M1.27M
Total Debt22.20M20.93M17.42M14.35M15.04M
Total Liabilities51.86M32.23M32.13M31.14M22.12M
Stockholders Equity63.89M12.65M11.78M28.03M114.00K
Cash Flow
Free Cash Flow-23.93M-10.86M-9.49M-9.47M3.99M
Operating Cash Flow-22.62M-10.80M-8.35M-7.10M4.22M
Investing Cash Flow-15.37M1.35M-1.17M-8.64M-234.00K
Financing Cash Flow28.24M27.20M3.78M21.99M-4.22M

MCI Onehealth Technologies, Inc. Class A Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price1.38
Price Trends
50DMA
1.39
Negative
100DMA
1.46
Negative
200DMA
1.55
Negative
Market Momentum
MACD
-0.02
Negative
RSI
54.76
Neutral
STOCH
61.31
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:AIDX, the sentiment is Neutral. The current price of 1.38 is above the 20-day moving average (MA) of 1.32, below the 50-day MA of 1.39, and below the 200-day MA of 1.55, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 54.76 is Neutral, neither overbought nor oversold. The STOCH value of 61.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:AIDX.

MCI Onehealth Technologies, Inc. Class A Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
$7.41B0.36-61.88%2.33%16.99%1.69%
44
Neutral
C$408.86M-58.84%290.03%54.58%
C$41.56M
C$13.67M-3.57%
C$5.79M2.8437.43%
C$6.74M
C$6.19M
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:AIDX
MCI Onehealth Technologies, Inc. Class A
1.38
-0.96
-41.03%
TSE:RHT.H
Reliq Health Technologies
0.22
0.00
0.00%
TSE:NPTH
Neupath Health Inc.
0.25
0.06
31.58%
TSE:JUMP
Leveljump Healthcare Corp.
0.06
0.00
0.00%
TSE:CDX.H
Cloud DX Inc
0.09
0.00
0.00%
TSE:KOVO
Kovo HealthTech Corporation
0.04
0.02
100.00%

MCI Onehealth Technologies, Inc. Class A Corporate Events

Product-Related AnnouncementsBusiness Operations and Strategy
HEALWELL AI Expands into U.S. Market with Orion Health Partnership
Positive
Jun 11, 2025

HEALWELL AI Inc. has announced its strategic expansion into the U.S. healthcare market by launching a suite of AI-enabled tools in collaboration with Orion Health’s established software offerings. This move is expected to enhance HEALWELL’s market presence by combining Orion Health’s extensive U.S. experience and infrastructure with HEALWELL’s AI capabilities, aiming to improve clinical outcomes and reduce administrative burdens. The expansion will focus on value-based care and population health initiatives, supported by a modular, FHIR-native repository to facilitate interoperability and real-time data sharing. HEALWELL plans to deepen its U.S. presence through strategic partnerships and acquisitions, positioning itself to support clinical research and development in the life sciences sector.

The most recent analyst rating on (TSE:AIDX) stock is a Buy with a C$2.50 price target. To see the full list of analyst forecasts on MCI Onehealth Technologies, Inc. Class A stock, see the TSE:AIDX Stock Forecast page.

Executive/Board ChangesM&A TransactionsBusiness Operations and StrategyFinancial Disclosures
HEALWELL AI Inc. Achieves Record Growth and Expands Global Reach with Orion Health Acquisition
Positive
May 13, 2025

HEALWELL reported a record revenue growth of 208% in Q1-2025, driven by acquisitions and a 224% increase in its AI and Data Science business. The acquisition of Orion Health is expected to significantly enhance HEALWELL’s financial performance and global reach, adding substantial SaaS and services revenue and expanding its customer base. Leadership changes have been announced to support the company’s growth and integration strategy. The company’s financial results exceeded expectations, with cost optimization efforts and secured financing further strengthening its financial position.

The most recent analyst rating on (TSE:AIDX) stock is a Buy with a C$2.50 price target. To see the full list of analyst forecasts on MCI Onehealth Technologies, Inc. Class A stock, see the TSE:AIDX Stock Forecast page.

Financial Disclosures
HEALWELL AI to Release Q1 2025 Financial Results
Neutral
May 6, 2025

HEALWELL AI Inc. is set to announce its Fiscal First Quarter 2025 financial results on May 13, 2025, and will hold a conference call and webcast to discuss the results. This announcement is significant for stakeholders as it provides insights into the company’s financial health and strategic direction, potentially impacting its market positioning and investor confidence.

Executive/Board ChangesBusiness Operations and Strategy
HEALWELL AI Inc. Announces Strategic Leadership Changes for Growth
Positive
Apr 23, 2025

HEALWELL AI Inc. has announced strategic changes to its executive leadership team to drive the next phase of growth and shareholder value creation. The company has appointed James Lee as the new CEO, with Dr. Alexander Dobranowski transitioning to President, and new roles for Sacha Gera as COO and Brad Porter as CCO. These changes are intended to support the integration of HEALWELL’s units and capitalize on market opportunities following the acquisition of Orion Health, positioning the company to redefine preventative healthcare through data science and AI.

M&A TransactionsBusiness Operations and Strategy
HEALWELL Acquires Orion Health, Strengthening Global Leadership in Healthcare AI
Positive
Apr 1, 2025

HEALWELL AI Inc. has completed the acquisition of Orion Health, a global healthcare intelligence platform, for approximately NZD$175 million. This acquisition is set to transform HEALWELL into a global leader in healthcare data interoperability and AI, enhancing its market position and enabling it to deliver improved healthcare outcomes through AI-driven insights. The acquisition is expected to bring substantial revenue synergies, operational efficiencies, and cost savings, strengthening HEALWELL’s financial profile and expanding its reach in the public sector.

M&A TransactionsBusiness Operations and Strategy
WELL Health to Acquire Major Stake in HEALWELL AI Amid Orion Health Acquisition
Positive
Mar 31, 2025

HEALWELL AI Inc. announced that WELL Health Technologies Corp. intends to exercise its call option to acquire a significant portion of HEALWELL’s shares, which will coincide with HEALWELL’s acquisition of Orion Health Holdings Limited. This move will give WELL substantial economic interest and voting rights in HEALWELL, allowing it to nominate a majority of the company’s board of directors, thereby strengthening its influence and control over HEALWELL’s strategic direction.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 13, 2025